Aduro BioTech
VerifiedAduro Biotech | Engineered Immunotherapy for Cancer.
Launch date
Market cap
-
Net debt
-
Enterprise valuation
$206—308m (Dealroom.co estimates Jan 2015.)
Berkeley California (HQ)
Deals in current and previous year:
| EUR | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | $0.0 | round | |
| investor investor investor investor investor investor investor | $0.0 | round | |
| investor investor | $0.0 | round | |
| N/A | $0.0 | round | |
| investor | $0.0 | round | |
* | N/A | $2.5m | Private Placement VC |
| Total Funding | 000k | ||
Related Content
Recent News about Aduro BioTech
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Aduro BioTech
Edit
ACQUISITION by Novartis Jun 2023